|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings alter the current model of how amylin targets the nervous system, and as a result may lead to obesity and type II diabetes mellitus.
|
30974231 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we have also reviewed the role of amylin in other conditions including obesity and AD.
|
31333136 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several other studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents.
|
29203236 |
2018 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agonists of the glucagon-like peptide-1 (GLP-1) receptor and analogs of human amylin have been studied for almost two decades due to their therapeutic potential to treat diabetes mellitus and obesity.
|
29729352 |
2018 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to examine the expression of resistin (Retn), amylin (Iapp), and dopamine receptor domain 5 (Drd5) genes previously suggested to contribute to the pathogenesis of obesity, albeit controversially.
|
29936463 |
2018 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, we are the first to show that obesity induces increases in peptide YY levels during the light cycle and amylin remains high throughout the light and dark cycle in obese animals.
|
29191090 |
2017 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The amylin hormone is overexpressed in individuals with pre-diabetic insulin resistance or obesity leading to amylin oligomerization and deposition in pancreatic islets.
|
26503000 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Islet amyloid polypeptide (IAPP) and irisin have emerged as potential browning hormones that hold high potential to treat obesity.
|
26398307 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic hypersecretion of the pancreatic hormone amylin is common in humans with obesity or prediabetic insulin resistance and induces amylin aggregation and proteotoxicity in the pancreas.
|
25146704 |
2014 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analogs of IAPP have been approved for the treatment of diabetes and are under investigation for the treatment of obesity.
|
23337872 |
2013 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small amylin oligomers were even elevated in nonfailing hearts from overweight/obese patients, suggesting an early state of accumulation.
|
22275486 |
2012 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leptin and the pancreatic hormones amylin and pancreatic polypeptide are being evaluated alone or in combination for the treatment of obesity, but their physiological regulation has not yet been fully elucidated.
|
18252898 |
2008 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, peripheral insulin resistance such as in chronic obesity results in increased IAPP and insulin secretion.
|
12431815 |
2002 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide.
|
12086946 |
2002 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to define the islet amyloid polypeptide (IAPP) levels in gestational diabetes mellitus (GDM) and their interrelationship with the insulin levels, we studied (1) the placental RNA from 10 women (5 with GDM and 5 normals) for IAPP expression by Northern blotting and (2) 10 women with GDM during a 100-gram oral glucose tolerance test and compared these with 11 normal women matched for obesity and age.
|
9251946 |
1997 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The causal factors for IAPP fibrillogenesis are unknown but abnormal synthesis or overproduction could be involved: stimulation of B-cell secretion in NIDDM by obesity, hyperglycaemia or suphonylurea therapy may promote amyloidosis and further aggravate islet pathology.
|
8529518 |
1995 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma concentrations of the recently described hormone amylin, which is cosecreted with insulin by the pancreatic beta cell, are reported to be elevated in various states of insulin resistance, including hypertension and obesity.
|
7649582 |
1995 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated plasma islet amyloid polypeptide levels have been demonstrated in some diabetic, glucose-intolerant, and obese individuals, as well as in rodent models of diabetes and obesity.
|
7929617 |
1994 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amylin is deficient in insulin-dependent diabetes mellitus, while plasma levels are elevated in insulin-resistant conditions such as obesity and impaired glucose tolerance.
|
8516954 |
1993 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Several lines of evidence now implicate elevated amylin levels in the pathogenic mechanisms underlying NIDDM, and suggest to us that the obesity which frequently accompanies this syndrome is a result of, rather than a risk factor for, NIDDM.
|
2690958 |
1989 |